Reviewer ID: **Date:**

Administration Details for Study	
Study ID: (Surname of 1st Author and Year of Publication) **Possibly related studies in this review:** **Multicentre Study:** ☐ Yes. Number of centres _____ ☐ No. **Country/countries:** **Funding Details:** Government Private Manufacturer Other (specify)**:** **Additional Info**:	**Study Design:** ☐ - RCT ☐ - Crossover study ☐ - Non-randomised comparative study ☐ - Prospective case series ☐ - Registry-based study **Duration of Study:** **Study start/end dates:** **Length of follow up:**

Aim of Study

Interventions investigated	
Interventions: ☐ - Imatinib at 600 mg per day ☐ - Imatinib at 800mg per day	**Comparators:** ☐ - Sunitinib (specify dose): ☐ - Best supportive care, defined as: _____ _____

Outcomes Reported	
Outcome:	**Tool Used in Assessment/Outcome defined as:**
☐ - Overall response	
☐ - Overall survival	
☐ - Disease free survival	
☐ - Progression-free survival	
☐ - Time to treatment failure	
☐ - Health-related quality of life	
☐ - Adverse effects of treatment	

Inclusion Criteria

Exclusion Criteria

Characteristics of Participants				
Characteristic	**Intervention 1**	**Comparator 1**	**Comparator 2**	**All**
Enrolled				
Randomised				
Analysed				
Number lost to follow up				
Age (mean/median, SD/IQR/range)				
Sex:	**F:** **M:**	**F:** **M:**	**F:** **M:**	**F:** **M:**
Stage of disease: ☐ - Unresectable ☐ - Metastatic ☐ - Recurrent ☐ - Advanced	No (%) at stage:	No (%) at stage:	No (%) at stage:	No (%) at stage:
Mutations of c-KIT present: ☐ - exon 9 ☐ - exon 11 ☐ - exon 13 ☐ - exon 17	No (%) with mutation	No (%) with mutation	No (%) with mutation	No (%) with mutation
Previous imatinib use: mg/day mg/day mg/day	No (%) on this dose	No (%) on this dose	No (%) on this dose	No (%) on this dose
Used imatinib at mg/day as: ☐ - neoadjuvant treatment ☐ - adjuvant treatment	No (%) affected	No (%) affected	No (%) affected	No (%) affected

Number/proportion of KIT positive patients (if not 100%):

Method of GIST diagnosis (if specified):

Method used to determine progression/response:
☐ - CT scan
☐ - FDG – PET scan

Additional Information on Participants

Interventions				
Description of intervention (e.g. dose, number of times taken per day, care provided etc)	**Intervention 1**	**Comparator 1**	**Comparator 2**	**All**
Results				
Outcome:	**Intervention 1**	**Comparator 1**	**Comparator 2**	**All**
Overall Response				
Overall Survival				
Disease-free survival				
Progression-free survival				
Time to treatment failure				
Health-related QoL				
Adverse Events				
General Information on Adverse Events:				

Adverse Events Reported	Intervention 1	Comparator 1	Comparator 2	All

Additional Study Information